Elisa Vega Avila

Prof. Dr. Elisa Vega Avila


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2025 in Antioxidants
Verified
Journal Article
Open access
PDF file
JAJhony Anacleto-Santos
Jhony Anacleto-Santos
RMRicardo Mondragón-Flores
Ricardo Mondragón-Flores
PCPerla Yolanda López Camacho
Perla Yolanda López Camacho
MVMaría Isabel Rivera Vivanco
María Isabel Rivera Vivanco
TLTeresa de Jesús López-Pérez
Teresa de Jesús López-Pérez
NRNorma Rivera
Norma Rivera
Pleopeltis crassinervata has demonstrated antimicrobial effects, including anti-Toxoplasma activity, which has been attributed to the presence of compounds such as terpenes and fatty acid methyl esters. In this study, the effects of P. crassinervata hexane subfraction one (Hsf1) on the Toxoplasma gondii tachyzoite ultrastructure were evaluated using TEM and SEM, and lytic cycle processes such as adhesion, invasion, and proliferation were evaluated using phase-contrast microscopy. Additionally, the antioxidant capacity of the subfraction and its main compounds (phytol and hexadecenoic acid methyl ester) were determined as well as their effects on parasite viability. Hsf1 exhibited a dose-dependent inhibitory effect on the lytic process at a concentration of 47.2 µg/mL. Among the eighteen compounds identified in this subfraction, six were evaluated, of which two (phytol and hexadecanoic acid methyl ester) significantly reduced the viability of T. gondii to 0.11% and 16.6%, respectively, at a concentration of 100 µg/mL. Additionally, Hsf1 demonstrated an antioxidant capacity of 30% as assessed using the ORAC method. The two active compounds also exhibited antioxidant properties, with antioxidant capacities of 13.33% and 33% for hexadecanoic acid methyl ester and phytol, respectively, at concentrations up to 15.4 mg/mL. Hsf1 showed membrane damage and conoid extrusion in T. gondii tachyzoites, suggesting direct interference with the lytic cycle of the parasite. These findings underscore the therapeutic potential of Hsf1 as a promising tool for controlling infections caused by T. gondii, thereby providing an alternative in the search for new antiparasitic agents. However, further research is required to determine the in vivo pharmacological effects and properties of these compounds with potential anti-Toxoplasma activity.

7 May 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
JAJhony Anacleto-Santos
Jhony Anacleto-Santos
EAElisa Vega Avila
Elisa Vega Avila
LPLeticia Pacheco
Leticia Pacheco
MLManuel Lacueva-Arnedo
Manuel Lacueva-Arnedo
AGAlicia Gómez-Barrio
Alicia Gómez-Barrio
NRNorma Rivera
Norma Rivera
Pleopeltis crassinervata is a fern documented in ethnobotanical records for its use in Mexican traditional medicine to treat gastric disorders and mouth ulcers. Consequently, conducting biological and pharmacological assays is crucial to validate the therapeutic efficacy of this plant within the context of traditional medicine. In the present study, we investigated the biological activity of extracts and fractions obtained from P. crassinervata organs against bacteria (Salmonella typhimurium, Salmonella typhi, Staphylococcus aureus, Proteus mirabilis, Shigella flexneri, Bacillus subtilis, Escherichia coli) and Trichomonas vaginalis using in vitro models. The precipitate fraction obtained from the frond methanolic extract showed significant antibacterial activity (minimal inhibitory concentration [MIC] 120 µg/mL) against the Staphylococcus aureus strain and was effective against both Gram-positive and Gram-negative bacteria. The hexane fraction also obtained from frond methanolic extract, showed a trichomonacidal effect with an IC50 of 82.8 μg/mL and a low cytotoxic effect. Hsf6 exhibited the highest activity against T. vaginalis, and the GC-MS analysis revealed that the predominant compound was 16-pregnenolone. The remaining identified compounds were primarily terpene-type compounds.

Verified
Journal Article
Open access
PDF file
FAFrancisco Alarcon Aguilar
Francisco Alarcon Aguilar
DTDiana Laura Torres-Chacón
Diana Laura Torres-Chacón
ASAlfredo Suárez-Alonso
Alfredo Suárez-Alonso
SESamuel Estrada-Soto
Samuel Estrada-Soto
LGLuis Enrique Gómez-Quiroz
Luis Enrique Gómez-Quiroz
Julio C Almanza-PerezJulio C Almanza-Perez
Julio C Almanza-Perez
Hepatocellular carcinoma is one of the most aggressive malignancies worldwide, with limited therapeutic options. Boswellia serrata Roxb., an Indian medicinal tree, produces a resin rich in essential oil and boswellic acids, particularly acetyl-11-keto-β-boswellic acid (AKBA), with demonstrated antiproliferative and pro-apoptotic activities. This study investigated the cytotoxic effects of B. serrata essential oil and AKBA on hepatocarcinoma Huh-7 cells in both monolayer and three-dimensional spheroid cultures and characterized the underlying molecular targets. Essential oil was extracted and analyzed by gas chromatography-mass spectrometry (GC-MS). Cytotoxicity was assessed using the cell counting kit-8 (CCK-8). Three-dimensional spheroid cultures were also established to evaluate anti-tumoral potential. Expression of cyclin D1, cyclin-dependent of kinase 4 (CDK4) (cyclin-dependent kinase inhibitor 1A (p21), E-cadherin, (alpha fetoprotein) AFP, epithelial cell adhesion molecule (EpCAM), Myeloid cell leukemia-1 (Mcl-1), and caspase-3 was analyzed by western blot. In addition, an in silico analysis was performed on the main constituents of B. serrata essential oil targeting 5-lipoxygenase (5LO). The results showed cytotoxic effects, with AKBA exhibiting greater potency than the essential oil. Cytotoxicity was associated with caspase-3-mediated apoptosis, with minimal effects on cell cycle and epithelial–mesenchymal transition markers. The in silico analysis predicted that some compounds may act as competitive inhibitors of the 5LO at the catalytic site and partially activate pro-apoptotic pathways. These data support the potential of B. serrata-derived compounds as novel anti-hepatocarcinoma agents, with AKBA and longifolene as leads for further preclinical and clinical research.

9 May 2026 in Microorganisms
Verified
Journal Article
Open access
PDF file
CVClaudia Jessica Castillo Villanueva
Claudia Jessica Castillo Villanueva
JAJhony Anacleto-Santos
Jhony Anacleto-Santos
TLTeresa de Jesús López-Pérez
Teresa de Jesús López-Pérez
BCBrenda Casarrubias-Tabarez
Brenda Casarrubias-Tabarez
TFTeresa I. Fortoul
Teresa I. Fortoul
NRNorma Rivera
Norma Rivera
Toxoplasma gondii is an obligate intracellular parasite of the phylum Apicomplexa and the causative agent of toxoplasmosis, a disease with a worldwide distribution that causes serious consequences in immunocompromised patients and during pregnancy. Current pharmacological treatments have significant limitations, including their toxicity, lack of efficacy against the chronic phase of the parasite, and low selectivity, highlighting the need to develop new therapeutic targets. One of the most promising targets is the fatty acid synthesis pathway II (FASII), a metabolic pathway located in the parasite’s apicoplast and absent in mammalian hosts. This review synthesizes the available evidence on FASII pathway inhibitors described to date, as well as their potential impact on the viability and development of T. gondii. Overall, the reviewed studies support the FASII pathway as an attractive therapeutic target for the development of more selective and effective treatments against toxoplasmosis.